Janakiram Naveena B, Clarke Megan A, Kai Mihoko, Wallace Tiffany A, Russo Sandra, Hecht Toby T, Kohn Elise C, Heckman-Stoddard Brandy
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD 20850, United States.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, United States.
J Natl Cancer Inst. 2025 May 1;117(5):833-839. doi: 10.1093/jnci/djae277.
The marked increase in the incidence and mortality associated with endometrial cancer over the past 2 decades is driven in part by rising rates of higher-grade, more aggressive endometrial cancers with variations in TP53, uterine serous cancers and their dedifferentiated component, uterine carcinosarcomas. Uterine serous cancer rates have been increasing among all racial and ethnic groups, with higher rates of this aggressive uterine cancer in Black women. The National Cancer Institute hosted a workshop in June 2023 to examine the diverse aspects of uterine serous cancers across epidemiology, biology, and molecular genetics and to advance knowledge from basic to preclinical and translational efforts. Key stakeholders, including basic scientists, clinical investigators, and patient advocates, came together to identify critical research gaps that, when addressed, would facilitate more comprehensive and rapid progress in understanding and ultimately treating uterine serous cancers across all patients. The National Cancer Institute released a supplemental funding opportunity (NOT-CA-24-044) in spring 2024 to facilitate rapid translation of these recommendations.
在过去20年中，子宫内膜癌的发病率和死亡率显著上升，部分原因是高级别、侵袭性更强的子宫内膜癌发病率上升，这些癌症存在TP53变异、子宫浆液性癌及其去分化成分、子宫癌肉瘤。子宫浆液性癌在所有种族和族裔群体中的发病率都在上升，黑人女性中这种侵袭性子宫癌的发病率更高。美国国立癌症研究所于2023年6月举办了一次研讨会，以研究子宫浆液性癌在流行病学、生物学和分子遗传学方面的不同层面，并推动从基础研究到临床前和转化研究工作的知识进步。包括基础科学家、临床研究人员和患者倡导者在内的关键利益相关者齐聚一堂，确定关键的研究空白，解决这些空白将有助于在理解并最终治疗所有患者的子宫浆液性癌方面取得更全面、快速的进展。美国国立癌症研究所于2024年春季发布了一项补充资金机会（编号NOT-CA-24-044），以促进这些建议的快速转化。
